1 / 18

ANDI Vision

Coordinating and Financing R&D in Developing Countries-moving beyond PDP's The ANDI Experience Solomon Nwaka CEWG on R&D Financing & Coordination, April 6, 2011. "Creating a sustainable platform for R&D innovation in Africa to address Africa’s own health needs". ANDI Vision.

kyne
Download Presentation

ANDI Vision

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Coordinating and Financing R&D in Developing Countries-moving beyond PDP'sThe ANDI Experience Solomon NwakaCEWG on R&D Financing & Coordination, April 6, 2011

  2. "Creating a sustainable platform for R&D innovation in Africa to address Africa’s own health needs" ANDI Vision

  3. ANDI touches 8 elements of the GSPOA • prioritizing research and development needs; • promoting research and development; • building and improving innovative capacity; • transfer of technology; • application and management of intellectual property; • improving delivery and access; • ensuring sustainable financing mechanisms; • establishing monitoring and reporting systems.

  4. Evolution of ANDI

  5. >500 people at ANDI Meeting Nairobi 2010

  6. Mapping & priority setting exercise supports ANDI establishment • Exploratory Research • Natural product / TM • Clinical • Marketing • Medicinal Chemistry • IP management • Regulatory • Manufacturing • Pre-clinical toxicology • Safety / pharmacology • API production

  7. Competency research centers exist • Cities with 30 or more articles published in the 2004 - 08 period • Total of 90 cities in 27 countries • 16,647 biomedical articles led by African authors included in analysis Note: Only top 40 cities by research output labeled SOURCE: Thomson Web of Science

  8. R&D collaborations biased externally e.g. HIV/AIDS SOURCE: Thomson Web of Science, UCINET

  9. Patent activity also biased externally SOURCE: Delphion, VantagePoint, UCINET

  10. ANDI approach has received political recognition WHA62.16, 2009: "ANDI is a key initiative aimed at supporting and promoting African led health product innovation…." AMCOST, 2010: "AMCOST welcomes…African Network for Drugs and Diagnostics Innovation (ANDI) and its anticipated contribution to the science, technology and innovation……''

  11. Governance • Hosting Agency • UNECA • Board • Co-Chaired by: Minister Mugo of Kenya (Health) Minister Pandor of South Africa (S&T) • 12 members with >75% from Africa • WHO, AfDB, UNECA • Secretariat • Operates through regional hubs Fund

  12. ANDI business model – network-based projects

  13. ANDI's IT platform - open access and secure components

  14. Technical progress & challenges • Centres of Excellence for health innovation in Africa being identified (public & private) • Call resulted in 130 applications being reviewed • Call for projects resulted in 207 project applications • Projects being reviewed & prioritized for funding • Key challenge is: $$$$$$$ • EU have provided seed funds

  15. Financing options • Trust Fund at UNECA • Seeking to grow to $30M p.a. in regular contributions in 5 years • Actively fund raising • Exploring • Additional Trust Funds with other partners • Endowment Fund • Potential to leverage financing for projects / infrastructure • National Resources (public and private) • Governments and development agencies • Development and trade banks • Foundations and others …….

  16. One measure of success in 5 - 10yrs

  17. Lessons learned through ANDI • Desire for regionally coordinated / facilitated approach • Support at technical, business and political levels important • Address interface between research and market access early • Local product manufacture, regulatory and IP issues • Need for alignment between public and private sectors • Interest from governments, development and private banks • Link to Regional Science, Technology and Innovation policies • Support for SMEs, manufacture and commercialization • R&D financing should consider ALL these opportunities and the potential power of catalytic financing and leverage at local level

  18. Future coordinating role may be required

More Related